1. Home
  2. ENTA vs ARQQ Comparison

ENTA vs ARQQ Comparison

Compare ENTA & ARQQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$11.37

Market Cap

377.5M

Sector

Health Care

ML Signal

HOLD

Logo Arqit Quantum Inc.

ARQQ

Arqit Quantum Inc.

BUY

Current Price

$13.93

Market Cap

402.3M

Sector

Technology

ML Signal

BUY

Company Overview

Basic Information
Metric
ENTA
ARQQ
Founded
1995
2017
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
377.5M
402.3M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
ENTA
ARQQ
Price
$11.37
$13.93
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
★ $21.83
N/A
AVG Volume (30 Days)
242.2K
★ 283.3K
Earning Date
11-16-2026
12-08-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 29.93
N/A
EPS
N/A
★ N/A
Revenue
★ $102,814,000.00
N/A
Revenue This Year
N/A
$368.30
Revenue Next Year
N/A
$214.22
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 16.48
N/A
52 Week Low
$10.20
$11.52
52 Week High
$17.15
$49.33

Technical Indicators

Market Signals
Indicator
ENTA
ARQQ
Relative Strength Index (RSI) 43.19 28.23
Support Level $10.86 $12.04
Resistance Level $13.95 $17.25
Average True Range (ATR) 0.64 1.56
MACD -0.08 -0.98
Stochastic Oscillator 28.14 1.46

Price Performance

Historical Comparison
ENTA
ARQQ

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About ARQQ Arqit Quantum Inc.

Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment, that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.

Share on Social Networks: